Oral News and Research

RSS

Cequent Pharmaceuticals' IND application for CEQ508 approved for clinical trial

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) approved Cequent's first IND (investigational new drug) application yesterday.

10 Dec 2009

DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA

Emisphere Technologies, Inc. today announced that an independent Data Monitoring Committee (“DMC”) informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis (“OP”) Phase 3 Study 2303 and the Osteoarthritis (“OA”) Phase 3 Study 2301 exploring the safety and efficacy of an oral formulation of salmon calcitonin to treat patients with osteoporosis and osteoarthritis of the knee.

10 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Uroplasty to publish 12-month results of its OrBIT Urgent PC Neuromodulation System trial

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted the 12-month results of the OrBIT Trial of its Urgent® PC Neuromodulation System that will be published in the January 2010 print edition of THE JOURNAL OF UROLOGY®.

10 Dec 2009

Washington Post, New York Times examine PEPFAR

The Washington Post examines the Obama administration's goal "to get the 'emergency' out of the President's Emergency Plan for AIDS Relief" and integrate HIV/AIDS programs more into the health infrastructure of recipient countries. A five-year strategy for PEPFAR was released last week.

9 Dec 2009

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pacific Beach BioSciences, Inc. today reported that it has granted non-exclusive rights to a large pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

9 Dec 2009

USPTO grants CyDex Pharmaceuticals patent for Captisol

CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled “Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof.” This patent, along with other previously issued technology patents, will provide broader protection for CyDex’s Captisol® technology until 2028.

9 Dec 2009

Hi-Tech Pharmacal reports net sales of $40.9M for the quarter ended October 31, 2009

Hi-Tech Pharmacal Co., Inc. today reported results for the quarter ended October 31, 2009.

9 Dec 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.

9 Dec 2009

AHS annual meeting focuses on myeloma, says IMF

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians— says a large number of abstracts – nearly a quarter of the presentations submitted this year to the annual meeting of the American Society of Hematology (ASH) were for myeloma, with one being presented at the prestigious plenary session.

9 Dec 2009

Report on the community-acquired pneumonia drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics -- levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.

9 Dec 2009

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

Report highlights the state of oral health for children and adults in the United States

Oral disease, primarily dental caries, is the most common pediatric disease and can lead to physical and psychological disabilities as well as significant morbidity in adulthood.

9 Dec 2009

New guidelines on the management of antithrombotic agents for endoscopic procedures published

According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures.

9 Dec 2009

IQWiG's report on autologous stem cell transplantation for soft tissue sarcoma

Due to a lack of suitable studies, it is unclear whether patients with soft tissue sarcoma can benefit from autologous haematopoietic stem cell transplantation. With this type of therapy, some of the patient's own (autologous) stem cells are removed at a convenient time and generally re-implanted after a course of high-dose chemotherapy.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Phase II clinical trial results of Doxorubicin Transdrug announced

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).

9 Dec 2009

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

In a statement today, StemSave(TM), Inc., the market leader in the field of stem cell recovery and cryo-preservation lauds research published in the November issue of the European Cells and Materials Journal citing the reconstruction of the human mandible bone with autologous dental pulp stem cells.

9 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

Oral News and Research

Cequent Pharmaceuticals' IND application for CEQ508 approved for clinical trial

DMC recommends Emisphere Technologies' to proceed with oral calcitonin trial for OP and OA

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Uroplasty to publish 12-month results of its OrBIT Urgent PC Neuromodulation System trial

Washington Post, New York Times examine PEPFAR

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

USPTO grants CyDex Pharmaceuticals patent for Captisol

Hi-Tech Pharmacal reports net sales of $40.9M for the quarter ended October 31, 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

AHS annual meeting focuses on myeloma, says IMF

Report on the community-acquired pneumonia drug market

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Report highlights the state of oral health for children and adults in the United States

New guidelines on the management of antithrombotic agents for endoscopic procedures published

IQWiG's report on autologous stem cell transplantation for soft tissue sarcoma

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Phase II clinical trial results of Doxorubicin Transdrug announced

New breakthrough study shows reconstruction of human mandible bone with dental stem cells

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News